Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New whooping cough vaccine shows promise for toddlers

NCT ID NCT07213089

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new booster vaccine called DTaPgen in 290 healthy toddlers aged 15 to 36 months. The goal was to see if it works as well as a currently licensed vaccine to protect against whooping cough, diphtheria, and tetanus. Children received a single shot, and researchers measured their immune response and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DTaPgen vaccine (recombinant acellular pertussis combined with diphtheria and tetanus)
What this could lead to
If successful, this could provide a new booster option to protect young children against whooping cough, potentially with fewer side effects than current vaccines.
What could go wrong
This is a mid-stage trial with only 290 toddlers, so results may not apply to all children. The vaccine may not prove as effective or safe as the licensed version in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

290 people

The number who actually took part.

Started

Jul 2020

Finished

May 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 36 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants will be eligible for inclusion if ALL of the following criteria are met at the time of screening: 1. 15 to 36 months of age at the time of vaccination. 2. Having completed the 3-dose DTwP or 3-dose DTaP vaccination (no interchange of DTwP and DTaP during primary immunization). 3. The parents or legal guardians of the participant are able to read and write. 4. The parents or legal guardians can provide written informed consent. 5. Healthy, as established by pertinent medical history and physical examination. Exclusion Criteria: A participant with ANY of the following criteria at study entry will not be eligible for participation 1. History of any significant medical illness such as, but not limited to, immune deficiency, renal, hepatic, cardiovascular, or endocrine disorder as determined by the investigator based on medical history and physical examination. 2. History of allergy or hypersensitivity to any vaccine (including its component). 3. History of any serious adverse event or neurological adverse event after vaccination. 4. Having received only 1 or 2 doses of DTwP or DTaP (incomplete primary immunization) after birth until the study enrollment. 5. Having received the 4th dose DTwP or DTaP vaccination. 6. Having experienced a physician diagnosed diphtheria or tetanus or pertussis illness within 1 year prior to recruitment. 7. Receipt of any vaccine within 28 days prior to enrollment (3 months for live-attenuated vaccines). 8. Planning to receive tetanus, diphtheria, pertussis or planning to participate in another clinical trial during the study period (approximately 1 year). 9. Receipt of blood or blood component or immunoglobulin within 3 months prior to recruitment. 10. History of receiving any immunosuppressive drug or systemic corticosteroid (more than 0.5 mg/kg of prednisolone or equivalent for more than 14 days) within 3 months prior to recruitment. 11. Any bleeding disorder. 12. Any abnormality of splenic or thymic function. 13. Any progressive or severe neurological disorder such as seizure disorder or Guillain- Barre syndrome; 14. History of any illness including cognitive impairment and psychiatric disease that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the participants due to participation in the study. 15. Fever as defined by body temperature more than 38 degree celsius at the time of enrollment (temporary exclusion criterion).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pertussis (whooping cough) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kamphaengphet Hospital

    Kamphaeng Phet, Changwat Kamphaeng Phet, 62000, Thailand

  • Phaholpolpayuhasena Hospital

    Kanchanaburi, Kanchanaburi, 71000, Thailand

  • Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University

    Bangkok, Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.